Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Acadia Pharmaceuticals Inc.

< Previous 1 2 3 Next >
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Stock Trading Halted Today
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.